The lancet. Gastroenterology & hepatologyHumansFemaleMaleMiddle AgedCholangiocarcinoma
Tinengotinib for adults with advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 trial.
Milind Javle, Christos Fountzilas, Chih-Yi Liao, Meredith Pelster, Daneng Li, Dustin Deming, Vaibhav Sahai, Lionel Kankeu Fonkoua, Allen Cohn, Parvez Mantry, Donald Richards, Edwin Kingsley, Frank Wu, Peng Peng, Katie Hennessy
Published: 202610.1016/S2468-1253(25)00230-4
Abstract
BACKGROUND: Cholangiocarcinoma is a rare, aggressive cancer often driven by FGFR2 fusions, which are targetable with inhibitors such as pemigatinib and futibatinib. However, resistance frequently develops due to acquired FGFR2 mutations. In this stud…
Preview only. Read the full abstract at the source